Inovio Pharmaceuticals Inc. 
 Moderna, Inovio Pharmaceuticals and Novavax are racing to develop vaccines that could protect against the new respiratory virus originating in China, as fears mount it could spread more widely.

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.

China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

New research shows that several members of the coronavirus family are susceptible to inactivation via a system developed by biomedical products company Cerus.

Moderna, Inovio Pharmaceuticals and Novavax are racing to develop vaccines that could protect against the new respiratory virus originating in China, as fears mount it could spread more widely.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA. (See Full Profile)